Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. is a U.S.-based clinical-stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). The company’s work centers on its GEODe™ platform and a pipeline of biologic drug candidates intended for diseases with significant unmet medical need.

26.63

— Tectonic Therapeutic, Inc.
	%
Discovery platform	0% Proprietary technology used to identify and engineer GPCR-targeted biologics.
Therapeutic proteins	50% Protein-based drug candidates designed to modulate GPCR activity.
Antibody therapeutics	30% Antibody-based biologics developed to alter GPCR signaling in disease.
Drug development programs	20% Preclinical and clinical-stage programs advancing candidates toward approval.

Tectonic does not currently sell approved products; its primary counterparties are research partners, clinical trial...

Clinical development vendorsprimary
CROs, CDMOs, and trial sites that execute research, testing, and manufacturing work.
Potential licensing partnerssecondary
Biopharma companies that could license or collaborate on GPCR biologics programs.
Future healthcare providers and patientsemerging
Hospitals, physicians, and patients who would use approved therapies in unmet-need diseases.

Tectonic is headquartered in Watertown, Massachusetts and is organized as a U.S. public company listed on Nasdaq...

•Headquartered in Watertown, Massachusetts, United States
•Listed on Nasdaq Global Market under ticker TECX
•Uses U.S. and foreign CRO/CDMO partners for development work
•Has supply-chain exposure to China through third-party manufacturing
•Clinical and regulatory activity is primarily U.S.-centered

The company’s strategy is to advance its GPCR-focused biologics platform into clinical development and build a pipeline...

Advance lead programs through development milestonesshort-term

Clinical-stage biotech value depends on demonstrating safety, activity, and differentiation.

Strengthen the GEODe™ platform and IP positionmedium-term

A stronger platform can generate additional candidates and improve partnering leverage.

Secure external funding and partnering optionsshort-term

Development programs require substantial capital before any product revenue exists.

Tectonic faces the classic risks of a clinical-stage biotech company: no approved products, dependence on successful...

critical

Clinical development failure

Drug candidates may not show sufficient safety or efficacy to advance or gain approval.

Scope: TX45, TX2100 and future GPCR biologics
Materiality: high

high

Financing risk

The company has no product revenue and must fund long development timelines externally.

Scope: Equity, debt, collaborations, licensing
Materiality: high

high

Manufacturing and supply-chain disruption

Clinical materials depend on third-party CDMOs and raw-material supply chains.

Scope: Drug substance and drug product for trials
Materiality: high

high

Intellectual property disputes

Biotech value depends heavily on patents, licenses, and freedom to operate.

Scope: Owned and in-licensed technology, product candidates
Materiality: high

medium

Geopolitical and China exposure

Use of a China-based manufacturer can create policy, trade, and continuity risk.

Scope: WuXi Biologics and related sourcing
Materiality: medium

Stock-based compensation

Affects R&D and G&A expense

Fair value measurement of liability-classified instruments

Can affect other income/expense and net loss

Research and development expense timing

Impacts comparability across periods

Going-concern and liquidity estimates

Important for evaluating capital needs

Tectonic Therapeutic, Inc.

Clinical development failure

Financing risk

Manufacturing and supply-chain disruption

Intellectual property disputes

Geopolitical and China exposure

Tectonic Financial, Inc.

Protagenic Therapeutics, Inc.\new

PLIANT THERAPEUTICS, INC.

Transcode Therapeutics, Inc.

Gain Therapeutics, Inc.

Eledon Pharmaceuticals, Inc.